|
1
|
Muhammad N, Mao Q and Xia H: CAR T-cells
for cancer therapy. Biotechnol Genet Eng Rev. 33:190–226. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee DW, Kochenderfer JN, Stetler-Stevenson
M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M,
Shah NN, et al: T cells expressing CD19 chimeric antigen receptors
for acute lymphoblastic leukaemia in children and young adults: A
phase 1 dose-escalation trial. Lancet. 385:517–528. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maude SL, Laetsch TW, Buechner J, Rives S,
Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers
GD, et al: Tisagenlecleucel in children and young adults with
B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kochenderfer JN, Dudley ME, Kassim SH,
Somerville RPT, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan
GQ, Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse
large B-cell lymphoma and indolent B-cell malignancies can be
effectively treated with autologous T cells expressing an anti-CD19
chimeric antigen receptor. J Clin Oncol. 33:540–549. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kochenderfer JN, Somerville RPT, Lu T, Shi
V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al:
Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T
cells are associated with high serum interleukin-15 levels. J Clin
Oncol. 35:1803–1813. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mikkilineni L and Kochenderfer JN:
Chimeric antigen receptor T-cell therapies for multiple myeloma.
Blood. 130:2594–2602. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan Z, Cao J, Cheng H, Qiao J, Zhang H,
Wang Y, Shi M, Lan J, Fei X, Jin L, et al: A combination of
humanised anti-CD19 and anti-BCMA CAR T cells in patients with
relapsed or refractory multiple myeloma: A single-arm, phase 2
trial. Lancet Haematol. 6:e521–e529. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qian L, Li D, Ma L, He T, Qi F, Shen J and
Lu XA: The novel anti-CD19 chimeric antigen receptors with
humanized scFv (single-chain variable fragment) trigger leukemia
cell killing. Cell Immunol. 304–305. 49–54. 2016.PubMed/NCBI
|
|
9
|
Lee DW, Gardner R, Porter DL, Louis CU,
Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the
diagnosis and management of cytokine release syndrome. Blood.
124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen AP, Setser A, Anadkat MJ, Cotliar J,
Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse
events of cancer treatments: The common terminology criteria for
adverse events version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis
LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T,
Lin Y, et al: Axicabtagene Ciloleucel CAR T-cell therapy in
refractory large B-cell lymphoma. N Engl J Med. 37:2531–2544. 2017.
View Article : Google Scholar
|
|
12
|
Hirayama AV, Gauthier J, Hay KA, Voutsinas
JM, Wu Q, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Riddell SR,
et al: High rate of durable complete remission in follicular
lymphoma after CD19 CAR-T cell immunotherapy. Blood. 134:636–640.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fried S, Avigdor A, Bielorai B, Meir A,
Besser MJ, Schachter J, Shimoni A, Nagler A, Toren A and Jacoby E:
Early and late hematologic toxicity following CD19 CAR-T cells.
Bone Marrow Transplant. 54:1643–1650. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hockings C, Kuhnl A, Wong S, Shah M, Inam
S, Patten P, Cuthill K, Pagliuca T, Yallop D, Benjamin R, et al:
Characterisation of early and late cytopenias in lymphoma patients
following treatment with antiCD19 CAR-T therapy. In Bone Marrow
Transplant. 55:Springernature. (London). 238–239. 2020.
|
|
15
|
Cordeiro A, Bezerra ED, Hirayama AV, Hill
JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG and Bar M:
Late events after treatment with CD19-targeted chimeric antigen
receptor modified T cells. Biol Blood Marrow Transplant. 26:26–33.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abramson JS, Palomba ML, Gordon LI,
Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG,
Andreadis C, et al: Lisocabtagene maraleucel for patients with
relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001):
A multicentre seamless design study. Lancet. 396:839–852. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagle SJ, Murphree C, Raess PW, Schachter
L, Chen A, Hayes-Lattin B, Nemecek E and Maziarz RT: Prolonged
hematologic toxicity following treatment with chimeric antigen
receptor T cells in patients with hematologic malignancies. Am J
Hematol. 96:455–461. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Strati P, Varma A, Adkins S, Nastoupil LJ,
Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F,
et al: Hematopoietic recovery and immune reconstitution after
axicabtagene ciloleucel in patients with large B-cell lymphoma.
Haematologica. 106:2667–2672. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rejeski K, Perez A, Sesques P, Hoster E,
Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J,
Bücklein V, et al: CAR-HEMATOTOX: A model for CAR T-cell related
hematological toxicity in relapsed/refractory large B-cell
lymphoma. Blood. 138:2499–2513. 2021. View Article : Google Scholar : PubMed/NCBI
|
